Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules

US11028143B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US

Inventors

• Yangbing Zhao · Cherry Hill, US
• Devon Shedlock · San Diego, US
• Carl H. June · Yeadon, US
• Xiaojun Liu · Nanhu, CN

Key dates

• Filing date: Jan 21, 2015
• Grant date: Jun 8, 2021
• Expiry date: Jan 21, 2035

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.